This is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study of elvucitabine versus lamivudine administered once daily to HIV infected subjects with a documented M184V variant.

Eligibility

Ages Eligible for Study:

18 Years to 65 Years (Adult)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

HIV infected, clinically stable, adults

HIVRNA 5000 -150,000, CD4 100

Genotypically documented M184V variant

Receiving stable ART.

Exclusion Criteria:

Hep B

HIV-1 genotype for 4 protease inhibitors

HIV-1 genotype positive for 2 NNRTI mutations

Previous therapy with system myelosuppressive potential within 3 months of study start

Use of Epogen or Neupogen

History of cirrhosis

Alcohol or drug dependence

Inability to tolerate oral medication

Women who are pregnant or breast feeding

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00405249